↓ Skip to main content

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

Overview of attention for article published in BMC Neurology, May 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
55 Mendeley
Title
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
Published in
BMC Neurology, May 2015
DOI 10.1186/s12883-015-0331-3
Pubmed ID
Authors

Guillaume Grolez, Caroline Moreau, Bernard Sablonnière, Guillaume Garçon, Jean-Christophe Devedjian, Sayah Meguig, Patrick Gelé, Christine Delmaire, Regis Bordet, Luc Defebvre, Ioav Z Cabantchik, David Devos

Abstract

Growing body of evidence suggests that Parkinson's disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iron chelator, deferiprone, reduces the abnormally high levels of iron in the SN. In order to determine CP's involvement in iron accumulation in SN and PD progression, we aim to compare the ability of iron chelation treatment to reducing both SN iron levels and motor handicap in PD patients according to the level of ceruloplasmin activity. We used a moderate chelation protocol with deferiprone (DFP) based on a, 6-month delayed-start paradigm, randomized placebo controlled clinical trial in 40 PD patients. CP-ferroxidase activity was determined in blood and CSF together with the D544E gene polymorphism (rs701753). Iron levels were determined by R2* MRI sequence and the motor handicap by the UPDRS motor score. After 6 to 12 months of DFP treatment, greater reductions in SN iron levels and UPDRS motor scores were obtained in patients with higher serum and CSF levels of CP-ferroxidase activity. After 6 months of DFP treatment, the AT genotype group displayed greater reduction of iron level in the SN with greater CSF and serum levels of CP activity than the AA genotype group. Although most of the DFP-treated patients displayed clinical and radiological improvements, those with the lower CP activity appeared to respond better to iron chelation. Larger RCTs are now needed to establish whether pharmacological modulation of CP activity could be an innovative neuroprotective strategy in PD. FAIR-PARK study (ClinicalTrials.gov reference: NCT00943748 ; French national reference number: 2008-006842-25). This study was approved by the French Drug Agency (ANSM) and the local institutional review board ("Comité de Protection des Personnes of Lille").

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
China 1 2%
Australia 1 2%
Unknown 52 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 22%
Student > Master 9 16%
Professor 6 11%
Researcher 6 11%
Student > Bachelor 5 9%
Other 12 22%
Unknown 5 9%
Readers by discipline Count As %
Medicine and Dentistry 13 24%
Neuroscience 6 11%
Agricultural and Biological Sciences 6 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Biochemistry, Genetics and Molecular Biology 4 7%
Other 9 16%
Unknown 12 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 May 2015.
All research outputs
#2,676,071
of 5,067,557 outputs
Outputs from BMC Neurology
#610
of 979 outputs
Outputs of similar age
#96,217
of 169,309 outputs
Outputs of similar age from BMC Neurology
#25
of 46 outputs
Altmetric has tracked 5,067,557 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 979 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,309 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.